Mumbai: The US Food and Drug Administration’s (FDA) latest draft guidelines aimed at making it faster and less costly to develop biosimilars-lower-priced close copies of complex biologic drugs-could be a big boost for Indian biotech companies, top industry officials said. Companies such as Biocon, Dr Reddy’s Laboratories and Intas, which are invested heavily in biosimilars,…
Homegrown drugmaker Cipla and Eli Lilly and Company (India) on Thursday announced an agreement to distribute and promote type 2 diabetes and chronic weight management drug tirzepatide under a new brand name, Yurpeak, in India. Tirzepatide was launched in India by Lilly in March 2025 under the brand name Mounjaro. Under the agreement, Cipla has…
US pharma major Eli Lilly has tied up with Indian drug major Cipla to market and distribute a second brand of its breakthrough weight-loss and diabetes drug tirzepatide in India. The drug under the new brand name, Yurpeak, will be priced the same as the existing Mounjaro brand, which was launched in India in mid-March….
Ongoing Sale of Covid-Era Liposomal Amphotericin B Challenged, SC Seeks Response from Top Pharma Firms, DCGI We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
The White House has shelved plans to impose tariffs on generic drug imports, a move that comes as a relief to Indian pharmaceutical companies, which supply nearly half of all generic prescriptions in the United States, The Times of India (TOI) has reported. The decision also reassures millions of Americans who rely on imported generics…
Mumbai: The US tariffs on India is a “wrong approach”, said Phil Murphy, governor of New Jersey and a senior Democratic party leader. On a recent visit to India, Murphy’s delegation focused on economic growth, government-level relations and collaboration for higher education. He emphasised India’s strong position as a key business ally for the US….
Mumbai: After last week’s pummelling of their shares by the threat of US tariffs, a powerful Indian pharma industry association hit back on issues raised by a section of observers in the US who red-flagged the quality of generic medicines supplied from facilities based in India and China. In its strongest point-wise rebuttal in recent…
US President Donald Trump’s Friday announcement of a 100% tariff on pharmaceutical products may not affect Indian pharma exports as the measure currently targets only “patented and branded products,” while India predominantly ships generic drugs to the US, experts said. “Because the 100% tariff is targeted at branded/patented drugs, most Indian generic exports would not…
Danish drug maker Novo Nordisk is set to launch in India Ozempic (semaglutide), its trailblazing once-a-week injectable brand that was originally approved to manage type 2 diabetes but found unprecedented demand for its significant benefits in patients with obesity or weight management issues. Approved first by the US FDA in 2017, Ozempic saw its global…
Leadership Shift at Cipla: Umang Vohra to Exit, Achin Gupta Likely to Take Over as Global CEO We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link